Neuropeptide Y: Risks & Legal Status

Critical Safety Information#

Neuropeptide Y is not approved for any therapeutic use. While it is an endogenous peptide with a strong biological rationale for stress and mood applications, its effects on appetite and cardiovascular function present significant safety considerations. Clinical data is limited to a single small trial.

Risk Categories#

Appetite Stimulation#

NPY is one of the most potent known orexigenic (appetite-stimulating) molecules. Central NPY signaling potently drives food intake through Y1 and Y5 receptors in the hypothalamus. Any therapeutic use of intranasal NPY must consider the potential for significant appetite increase and weight gain, particularly with repeated administration.

Cardiovascular Effects#

NPY is co-released with norepinephrine from sympathetic nerves and acts as a vasoconstrictor through Y1 receptors on vascular smooth muscle. It has been implicated in stress-related cardiovascular responses. Exogenous NPY administration could potentially elevate blood pressure and affect cardiac function.

Limited Clinical Evidence#

The clinical safety database consists of a single 30-patient RCT with single-dose administration. The effects of repeated or chronic intranasal NPY on appetite, body weight, blood pressure, and other parameters are unknown.

Legal and Regulatory Status#

Risk Assessment Context#

Neuropeptide Y belongs to the Neuropeptide category of research peptides. Risk assessment for Neuropeptide Y should consider both the compound-specific risks identified in clinical research and the broader regulatory environment. Researchers and healthcare providers should evaluate these risks in the context of the specific patient population and therapeutic indication.

Risk Categories#

The following risk categories have been identified for Neuropeptide Y based on available evidence and regulatory assessments:

Appetite Stimulation#

NPY is one of the most potent orexigenic peptides. Therapeutic use could cause significant appetite increase and potential weight gain.

Cardiovascular Effects#

NPY is a potent vasoconstrictor through Y1 receptors on vascular smooth muscle and a co-transmitter in sympathetic nerves. It may increase blood pressure and affect cardiovascular function.

Early-Stage Clinical Development#

Only one small RCT (n=30) has been published for intranasal NPY. The safety profile from chronic administration is unknown.

Regulatory Status by Jurisdiction#

The regulatory and legal status of Neuropeptide Y varies by country and jurisdiction. Researchers should verify current regulations before acquiring or using this compound.

Regulatory classifications can change. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction.

Important Warnings#

The following warnings apply to Neuropeptide Y:

• NOT APPROVED: Intranasal NPY is in early-phase clinical trials and is not approved for any therapeutic use.
• APPETITE EFFECTS: NPY is one of the most potent appetite stimulators. Use may cause significant hunger and potential weight gain.
• CARDIOVASCULAR RISK: NPY causes vasoconstriction and may increase blood pressure. Use extreme caution in individuals with cardiovascular disease.

These warnings are based on available preclinical and clinical data. The absence of a warning does not indicate safety. Consult qualified professionals before making any decisions regarding peptide research.

Related Reading#

• Neuropeptide Y overview and research guide
• Neuropeptide Y side effects profile
• Neuropeptide Y research evidence